Twitter Facebook LinkedIn WhatsApp Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2023 July 19, 2023 argenx announces full exercise of underwriters’ option to purchase additional ADSs July 18, 2023 argenx raises $1.1 billion in gross proceeds in a global offering July 17, 2023 argenx announces launch of proposed global offering July 17, 2023 argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy June 30, 2023 argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China June 20, 2023 argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis June 20, 2023 argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy May 31, 2023 argenx to Present at Upcoming Investor Conferences May 4, 2023 argenx Reports First Quarter 2023 Financial Results and Provides Business Update May 3, 2023 argenx announces results of Annual General Meeting of Shareholders May 2, 2023 argenx to Present at BofA Securities 2023 Health Care Conference April 27, 2023 argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023 Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
